DSDaan S. Spoor

Daan S. Spoor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daan S. Spoor has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cardiac Radiation Dose and Subclinical Coronary Artery Disease Progression after Breast Cancer Radiotherapy: 2-year Cardiac CT Results from the EARLY-HEART Study

    by Elie Mousseaux, Damian Craiem, Rozemarijn Vliegenthart, Sophie Jacob, Arantxa Eraso, Susana Constantino Rosa Santos, Kai Borm, Johannes A. Langendijk, Médéa Locquet, Montse Ventura, et al.

    Two years after breast cancer radiotherapy, cardiac CT demonstrated dose-associated progression of coronary artery calcification, particularly in the presence of preexisting calcification, while coronary stenosis progression was unrelated to radiation dose.


  • Cardiac MRI–based Subclinical Cardiac Dysfunction during 2 Years after Breast Cancer Irradiation: The MEDIRAD EARLY-HEART Study

    by Jérôme Lamy, Daan S. Spoor, Johannes A. Langendijk, Rozemarijn Vliegenthart, Arantxa Eraso, Montserrat Ventura, Susana Constantino Rosa Santos, Manuela Fiúza, Nadjia Kachenoura, Anne P. G. Crijns, et al.

    Higher cardiac radiation doses in participants with breast cancer treated with radiation therapy after lumpectomy were associated with increased risk of reduced left ventricular global longitudinal strain at 2-year follow-up cardiac MRI.


  • Open Access

    A comparison of cardiovascular and pulmonary morbidities and risk factors in breast cancer survivors compared to an age-matched female control group in the Lifelines prospective population cohort

    by D.S. Spoor, V.A.B. van Den Bogaard, N.M. Sijtsema, P. Van der Meer, G.H. de Bock, J.A. Langendijk, J.H. Maduro, A.P.G. Crijns


  • Open Access

    Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer: Protocol for a European Multicenter Prospective Cohort Study (MEDIRAD EARLY HEART Study)

    by Valentin Walker, Anne Crijns, Johannes Langendijk, Daan Spoor, Rozemarijn Vliegenthart, Stephanie E Combs, Michael Mayinger, Arantxa Eraso, Ferran Guedea, Manuela Fiuza, et al.

    Breast cancer is the most common cancer among women, and radiotherapy plays a major role in its treatment. However, breast cancer radiotherapy can lead to incidental irradiation of the heart, resulting in an increased risk for a variety of heart diseases arising many years after radiotherapy. Therefore, identifying breast cancer patients at the highest risk for radiation-induced cardiac complications is crucial for developing strategies for primary and secondary prevention, which may contribute to healthy aging. There is still a need for precise knowledge on the relationship between radiation dose to specific cardiac structures and early subclinical cardiac changes and their occurrence over time that could finally lead to cardiac complications. The MEDIRAD EARLY HEART study aims to identify and validate new cardiac imaging and circulating biomarkers of radiation-induced cardiovascular changes arising within first 2 years of breast cancer radiotherapy and to develop risk models integrating these biomarkers combined with precise dose metrics of cardiac structures based on three-dimensional dosimetry. The EARLY HEART study is a multicenter, prospective cohort study in which 250 women treated for breast cancer and followed for 2 years after radiotherapy will be included. Women treated with radiotherapy without chemotherapy for a unilateral breast cancer and aged 40-75 years meet the inclusion criteria. Baseline and follow-up data include cardiac measurements based on two-dimensional speckle-tracking echocardiography, computed tomography coronary angiography, cardiac magnetic resonance imaging, and a wide panel of circulating biomarkers of cardiac injury. The absorbed dose will be evaluated globally for the heart and different substructures. Furthermore, the dose-response relationship will allow modeling the radiation-induced occurrence and evolution of subclinical cardiac lesions and biomarkers to develop prediction models. This study details the protocol of the MEDIRAD EARLY HEART study and presents the main limits and advantages of this international project. The inclusion of patients began in 2017. Preliminary results are expected to be published in 2019, and complete analysis should be published in 2021. The MEDIRAD EARLY HEART study will allow identifying the main cardiac imaging and blood-based determinants of radiation-induced cardiac injuries to better propose primary and secondary preventive measures in order to contribute to enhanced patient care and quality of life. ClinicalTrials.gov NCT03297346; https://clinicaltrials.gov/ct2/show/NCT03297346 (Archived by WebCite at http://www.webcitation.org/72KS7MIUU). RR1-10.2196/9906.


  • Open Access

    Early detection of cardiovascular changes after radiotherapy for breast cancer: Protocol for a European multicenter prospective cohort (MEDIRAD EARLY HEART Study) (Preprint)

    by Valentin Walker, Anne Crijns, Johannes Langendijk, Daan Spoor, Rozemarijn Vliegenthart, Stephanie Combs, Michael Mayinger, Arantxa Eraso, Ferran Guedea, Manuela Fiuza, et al.

    BACKGROUND Breast cancer (BC) is the most common cancer among women and radiotherapy (RT) plays a major role in its treatment. However, BC RT can lead to incidental irradiation of the heart, resulting in an increased risk of a variety of heart diseases arising many years after radiotherapy. Therefore, identifying BC patients with the highest-risk of radiation-induced cardiac complications is crucial for developing strategies for primary and secondary prevention, which may contribute to healthy ageing. There is still a need of precise knowledge on the relationship between radiation dose to specific cardiac structures and early subclinical cardiac changes and their occurrence in time that could finally lead to cardiac complications. OBJECTIVE The MEDIRAD EARLY HEART study aims to identify and validate new cardiac imaging and circulating biomarkers of radiation-induced cardiovascular changes arising in the first 2 years after BC RT and to develop risk models integrating these biomarkers combined with precise dose metrics of cardiac structures based on 3D-dosimetry. METHODS EARLY HEART study is a multicenter prospective cohort study that will include 250 women treated for breast cancer and followed for 2 years after RT. Women treated with RT without chemotherapy, for a unilateral breast cancer and aged 40 to 75 years meet the inclusion criteria. Baseline and follow-up data include cardiac measurements based on 2D-speckle-tracking-echocardiography, on coronary computed tomography angiography, on cardiac magnetic resonance imaging and a wide panel of circulating biomarkers of cardiac injury. The absorbed dose is evaluated globally for the heart and different substructures. Dose-response relationship will allow modeling radiation-induced occurrence and evolution of subclinical cardiac lesions and biomarkers in order to develop prediction models. RESULTS The article details the protocol of the MEDIRAD EARLY HEART study, and presents main limits and advantages of this international project. Inclusion of patients began in 2017. Preliminary results are expected to be published in 2019, and complete analysis should be published in 2021. CONCLUSIONS The MEDIRAD EARLY HEART study will allow identifying the main cardiac imaging and blood-based determinants of radiation-induced cardiac injuries to better propose primary and secondary preventive measures in order to contribute to enhanced patients’ care and quality of life. CLINICALTRIAL Clinicaltrials.gov NCT03297346 - https://clinicaltrials.gov/ct2/show/NCT03297346